Fig. 3: Overall survival.
From: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Hazard ratio repeated CI: 0.166–1.322.
Fig. 3: Overall survival. | Nature Medicine
From: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Hazard ratio repeated CI: 0.166–1.322.
